Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2Thoracic 1NET 1Head & Neck 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 65Neoplasm Metastasis 56Leukemia, Myeloid, Acute 55Multiple Myeloma 44Prostatic Neoplasms 43Melanoma 43Lung Neoplasms 39Colorectal Neoplasms 35Lymphoma 33Pancreatic Neoplasms 30Leukemia, Lymphocytic, Chronic, B-Cell 30Carcinoma, Non-Small-Cell Lung 29Myelodysplastic Syndromes 26Squamous Cell Carcinoma of Head and Neck 25Lymphoma, Large B-Cell, Diffuse 25Triple Negative Breast Neoplasms 22Neoplasms 22Ovarian Neoplasms 21Burkitt Lymphoma 21Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Carcinoma, Renal Cell 18Sarcoma 17Lymphoma, Mantle-Cell 17Glioma 17Uterine Cervical Neoplasms 16Rectal Neoplasms 16Leukemia, Myelomonocytic, Chronic 15Fallopian Tube Neoplasms 15Stomach Neoplasms 14

Interventions

3-Iodobenzylguanidine 8Temozolomide 6lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 4anlotinib 4Specimen Handling 4Everolimus 4Radiotherapy 3Phenoxybenzamine 3Magnetic Resonance Spectroscopy 3Doxorubicin 36-fluorodopamine 3olaparib 2cabozantinib 2belzutifan 2Nivolumab 2Ifosfamide 2Fluorodeoxyglucose F18 2Filgrastim 2Doxazosin 2Dexmedetomidine 2Capecitabine 2Biopsy 2Axitinib 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vatalanib 1vandetanib 1tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Pheochromocytoma × Biopsy × Clear all
NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT05142241 2025-11-18

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
14 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡